Taxcor Plus Receives European Approval

The coronary stent system produced by Eurocor GmbH has now received European CE mark approval.

BONN, Germany, January 26 - "Taxcor Plus was developed over years of research. We are expecting
outstanding clinical results," says Dr. Rembert Pogge von Strandmann,
Clinical Director at Eurocor GmbH. "So the European CE approval is just a
logical next step." The approval forms the basis for worldwide sale of the
new system, with the exception of the USA.

The combination of medication and mechanical intervention in Taxcor Plus,
which is produced from cobalt chrome, offers unique medical advantages to
patients. For one, the flexibility of the stent reduces trauma to the
coronary artery and leads to optimal adaptation to the body. Moreover, the
medication Paclitaxel, which coats the stent, inhibits any negative effects
on the coronary blood vessels that may result from the minimally-invasive
procedure.

The bioactive structure of the stent surface allows it to be coated with
Paclitaxel without using polymers. This avoids the increased risk of
inflammation, sensitivity reactions or delayed recovery. Taxcor Plus
therefore offers patients a highly efficient therapy which is also as safe as
possible.

Less friction minimises complications

The newest stent solution from Eurocor is based on the principles of
biomechanics. The structure of the Taxcor stent features an especially small
volume of metal as well as high flexibility, which reduces the trauma to the
stented coronary artery usually caused by the permanent friction that results
from the use of more rigid stents.

Lower burden on patients due to short medication delivery time

The full dose of the medication is quickly delivered to the arterial wall
where it inhibits cell division, which in turn prevents restenosis. It is
also effective against the processes of inflammation.

The company

Eurocor GmbH is a rapidly growing life sciences company specialising in
research and development, and production of cardiovascular catheter and
coronary stent technologies. The products of the Bonn-based company, which
are implanted during minimally-invasive heart interventions, are based on
biological and biomechanical principles to make them especially flexible and
adaptable. To deliver medication via a balloon catheter, Eurocor has
developed an innovative method that is especially well-tolerated by patients.

    Press contact:
    Blattwerk, Hamburg
    Phone: +49(0)40-41537634
    Email: eurocor@blattwerk-kommunikation.de

Press contact: Blattwerk , Hamburg, Phone: +49(0)40-41537634, Email: eurocor at blattwerk-kommunikation.de